Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

AtaiBeckley

AtaiBeckley Inc.

HQ
United States
Registry
SEC EDGAR · CIK 2081043
Status
acquired
Listing
Private
Current stage
wholly owned subsidiary of Eli Lilly and Company since 2026-09-11; Form 15 deregistration intended
Key people
All directors and executive officers resigned at the Effective Time 2026-09-11; directors now Christopher Anderson and Jonathan R. Haug; officers Jonathan R. Haug (President), Steffanie Lim-Ho (Treasurer), Christopher Anderson (Secretary), Jonathan Groff and Jamie Burnett (Assistant Secretaries), Katie Lodato (Assistant Treasurer). Retention bonus of $194,000 approved 2026-09-10 for COO Gerd Kochendoerfer
Investors
Eli Lilly and Company (100%). Apeiron Investment Group Ltd, Apeiron Presight Capital Fund II, Presight Capital Management I and Fabian Hansen report 0 shares on Schedule 13D/A No. 5, event date 2026-09-11

sec.govregistryverified 2026-09-15

Notes on the record

Formed from the atai / Beckley Psytech combination. IR address 250 West 34th Street, New York. Sponsor of record on ClinicalTrials.gov for VLS-01 is 'atai Therapeutics, Inc.' and for BPL-003 is 'Beckley Psytech Limited'; a sponsor search on 'AtaiBeckley' returns zero records. See D001-lilly-ataibeckley-2026. Supersedes the row verified 2026-08-25. Stockholder approval 2026-09-08 (8-K Item 5.07); merger closed 2026-09-11 (8-K Items 2.01, 3.01, 5.01, 5.02, 5.03); fifteen Form 4s filed 2026-09-11 report cancellation of insider options and RSUs for cash plus CVRs; POS AM and POSASR filed 2026-09-11 deregister unsold shares.

Assets

  • BPL-003

    Phase 2b complete; company stated Phase 3 activities initiated (Q2 2026 10-Q); no Phase 3 record on ClinicalTrials.gov or CTIS as of 2026-09-15. Sweeps 2026-09-15: intervention BPL-003 OR mebufotenin OR VLS-01 with Phase 3 filter returns 0; sponsor Beckley Psytech 7 records, max Phase 2; sponsor atai Therapeutics 3, max Phase 2; sponsor AtaiBeckley 0; sponsor Eli Lilly with those interventions 0; CTIS BPL-003 1 record (2024-513457-70-00, Ended). NCT05870540 record updated 2026-09-10, status COMPLETED unchanged · treatment-resistant depression; separate Phase 2 in alcohol use disorder

    clinicaltrials.govregistryverified 2026-09-15

Registered trials

  • NCT05347849ClinicalTrials.gov

    PHASE1 · Pharmacokinetics in Healthy Adults · COMPLETED · United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05660642ClinicalTrials.gov

    PHASE2 · Treatment Resistant Depression · RECRUITING · United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05674929ClinicalTrials.gov

    PHASE2 · Alcohol Use Disorder · COMPLETED · United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05870540ClinicalTrials.gov

    PHASE2 · Treatment Resistant Depression · COMPLETED · Australia, Germany, Poland, Spain, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-09-15

  • 2024-513457-70-00CTIS

    Therapeutic exploratory (Phase II) · Treatment-Resistant Depression (TRD) · Ended · Germany, Poland, Spain

    euclinicaltrials.euctis registryverified 2026-08-31

Deals

In the briefing

7 issues tagged ATAIBECKLEY.